Skip to Content

Month: January 2023

FDA declines to grant accelerated approval for Eli Lilly’s experimental Alzheimer’s treatment

By John Bonifield and Jacqueline Howard, CNN The US Food and Drug Administration declined to grant accelerated approval to an experimental Alzheimer’s drug, donanemab, and requested additional data from Eli Lilly and Company, the drug maker. The company, which announced the development on Thursday, plans to file Phase 3 clinical trial data later this year

Continue Reading